List
The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.
-
Satellite Ground Station Network for Real-Time Space Weather Data
SBC: USML L.L.C. Topic: 843WThe goal of this Phase II effort is to carry out a series of tasks with the purpose of developing a ground station network that can provide less than 15 minute latency in acquiring data from NOAA space weather assets. These tasks include: Finalize a set of specifications for ground stations so they can be used to determine the suitability of existing ground stations for the different missions ...
SBIR Phase II 2017 Department of Commerce -
PLATFORM FOR NEUROCOGNITIVE EVALUATION AND MONITORING
SBC: ENFORMIA INC. Topic: NCICurrent standardized neuropsychological tests are based on decades old paper and pencil methods They lack reliability sensitivity specificity repeatability and require trained neuropsychologists to administer them Their administration in clinical and research settings result in high cost complexity and inconsistent results There is a need and a commercial opportunity for an extensible co ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
An RNA targeted platform for anti flavivirus drug discovery
SBC: Ribometrix LLC Topic: NIAIDSUMMARY Emerging and re emerging mosquito borne flaviviruses cause widespread mortality morbidity and economic burden Options for prevention and treatment of mosquito borne flaviviruses are limited Flavivirus vaccines face unique development challenges no antiviral therapies are available and the mosquito vectors have proven difficult to eradicate Despite vaccines against Yellow Fever and J ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Enhancing cytarabine efficacy in leukemia through CDK inhibition
SBC: SENEX BIOTECHNOLOGY, INC. Topic: 102Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Peptide based tool for the rapid isolation of quiescent monocytes from peripheral blood
SBC: AFFINERGY, LLC Topic: 102SUMMARY ABSTRACT Dendritic cell DC therapy represents a new and promising immunotherapeutic approach for treatment of advanced stage cancers with DC vaccines already approved for use in advanced prostate cancer and more than DC based vaccines in the clinical development pipeline for other cancers In particular the US market for cancer vaccines including DC based vaccines is set to expan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel injectable resiquimod formulation for treatment of metastatic cancers
SBC: Curebiotech, Inc. Topic: NCIPROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens
SBC: Theragnostic Technologies Inc. Topic: NIAIDAbstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Nitric Oxide Polymer Platform for the Prevention and Treatment of Infected Wounds
SBC: IFYBER, LLC Topic: NIAIDThis proposed SBIR research effort will lay the foundation for commercializing a new class of biomaterial for the prevention and treatment of infected skin wounds thereby enhancing patient health through improved patient outcome and reduced patient morbidity Specifically we will focus on evaluating and developing a biomaterial comprised of a nitric oxide NO releasing based on a commonly used ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel enzyme inhibitor screening platform using modified designer nucleosomes
SBC: EPICYPHER, INC. Topic: 300Project Summary Nucleosomes are the basic units of chromatin comprised of a histone octamer made up of two copies of each of the histone subunits H A H B H and H Changes in chromatin structure and function are mediated through histone post translational modifications PTMs such as methylation and ubiquitination Alterations of specific PTMs are highly associated with human diseases i ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic S nitrosothiol Sensor
SBC: CLINICAL SENSORS, INC. Topic: 400PROJECT SUMMARY This Small Business Innovation Research SBIR Phase I project aims to develop an accurate rapid and commercially available microfluidic sensor that measures low molecular weight S nitrosothiols in biological samples S nitrosothiols RSNOs the primary transporters of nitric oxide NO in physiology play a critical role for NOandapos s bioactivity Homeostatic control of low ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health